跳转到主要内容


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

新闻

Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma

In a recent contribution to the Citeline CEO Conclave's white paper on "Vision 2030: Growth Trajectory and Opportunities for Indian Pharma," Kalpeshkumar N. Modi, Vice President and Regional Sales Head at Dr. Reddy's Laboratories, highlighted the company's strategic moves towards innovation and collaboration in the pharmaceutical industry.

During the challenging times of the Covid-19 pandemic, Dr. Reddy's actively pursued in-licensing and partnering opportunities, demonstrating substantial momentum. Notable collaborations include agreements with Eli Lilly for baricitinib, MSD for Molnupiravir, and, more recently, partnerships with Chinese company Pregene for an anti- BCMA CAR-T cell therapy injection designed for multiple myeloma. Additionally, the company entered into agreements with Wellington Zhao Tai Therapies for an exclusive license to its CAR-T cell technology.

Dr. Reddy's commitment to expanding its therapeutic portfolio is evident in in-licensing deals with Jiangsu Hengrui Pharmaceuticals Co., Ltd for a breast cancer therapy called pyrotinib, and with Shanghai Junshi Biosciences Co. Ltd. to develop and commercialise toripalimab, an anti-PD-1 monoclonal antibody, across 21 countries. The company's B2B initiatives focus on fostering direct partnerships to support big pharma in product lifecycle management and collaborating with smaller companies engaged in drug development under the 505(b)(2) approval process.

Known for its leadership in digitisation efforts to enhance productivity and foster continuous improvement, Dr. Reddy's is also capitalising on CDMO opportunities. The company's subsidiary, Aurigene Pharmaceutical Services, is dedicated to discovery, development, and manufacturing for global R&D-driven biopharma companies. This involves building value-added partnerships, such as those aimed at developing cell and gene therapies, reducing the cost of CAR T-cell therapy, and innovating therapeutic solutions.

“We are continuing to work toward strengthening our position as a partner of choice,” said Kalpeshkumar N. Modi, Vice President, and Regional Sales Head of Dr. Reddy’s Laboratories.

White Paper Link - https://bit.ly/3uMkwfJ

Contact Us

请填写以下表格,我们会尽快与您联系.

给我们发电子邮件: api@drreddys.com | +91 40 49002222

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。

X

Dr.Reddy's

Book your slot to
explore our API solutions firsthand!

Schedule a meeting at CPHI China